Get the Stockscreener App
11.43
0.53%
0.09
Delcath Systems Inc stock is traded at $11.43, with a volume of 230.04K.
It is up +0.53% in the last 24 hours and up +9.09% over the past month.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$11.34
Open:
$11.32
24h Volume:
230.04K
Relative Volume:
0.57
Market Cap:
$394.58M
Revenue:
$85.23M
Net Income/Loss:
$2.70M
P/E Ratio:
182.01
EPS:
0.0628
Net Cash Flow:
$20.97M
1W Performance:
+1.24%
1M Performance:
+9.09%
6M Performance:
+32.40%
1Y Performance:
-25.44%
1-Day Range:
$11.01
$11.72
1-Week Range:
$10.79
$12.27
52-Week Range:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.43 | 391.48M | 85.23M | 2.70M | 20.97M | 0.0628 |
ABT
Abbott Laboratories
|
83.69 | 146.92B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.27 | 112.88B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.28 | 98.63B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.62 | 80.41B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.11 | 45.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Liver cancer-focused Delcath heads to Nasdaq BioConnect investor conference May 19 - Stock Titan
TradingKey - TradingKey
Delcath Systems Q1 2026: -$0.03 EPS Tops Estimates — Deep Dive - AlphaStreet
Tangible book value per share of Delcath Systems, Inc. – SWB:DV3R - TradingView
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results - MarketBeat
Delcath Systems Balances Growth with Rising Costs - TipRanks
Q1 2026 Delcath Systems Inc Earnings Call Transcript - GuruFocus
MSN Money - MSN
Delcath Systems, Inc. (DCTH) Stock Analysis: Aiming for an 89.80% Upside in the Medical Device Sector - DirectorsTalk Interviews
Uveal Melanoma Treatment Market is expected to Hit US$ 2.7 - openPR.com
Delcath Systems (DCTH) Trailing Profitability Flip Tests Bullish Margin Expansion Narrative - Sahm
Delcath Systems Reports First Quarter 2026 Results and Business Highlights - BioSpace
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 - BioSpace
Number of shareholders of Delcath Systems, Inc. – DUS:DV3R - TradingView
Delcath Systems Q1 Earnings Call Highlights - MarketBeat
Delcath Systems, Inc. (DCTH) reports Q1 loss, misses revenue estimates - MSN
Earnings call transcript: Delcath Systems Q1 2026 beats EPS forecast, stock rises - Investing.com
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
DCTH: Q1 saw record patient starts, 36% volume growth, and strong 2026 revenue guidance - TradingView
Delcath presents data on liver cancer treatment in breast cancer patients By Investing.com - Investing.com South Africa
Delcath presents data on liver cancer treatment in breast cancer patients - Investing.com UK
Delcath Systems Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Delcath Systems (NASDAQ:DCTH) Surpasses Q1 Estimates, Guidance Points to Continued Growth - ChartMill
Delcath Systems | 10-Q: Q1 2026 Earnings Report - Moomoo
Delcath Systems (NASDAQ: DCTH) grows Q1 2026 sales but posts small loss - Stock Titan
DELCATH SYSTEMS ($DCTH) Releases Q1 2026 Earnings - Quiver Quantitative
Delcath (NASDAQ: DCTH) Q1 revenue hits $25M with 2026 outlook of $100M+ - Stock Titan
Delcath Systems Sees Positive Adjusted EBITDA for 2026 >DCTH - Moomoo
Cancer treatment company targets $100M sales with 29 centers active - Stock Titan
A liver-targeted breast cancer procedure drew new data at ESMO - Stock Titan
Delcath Systems Q1 2026 Earnings Call Transcript - MarketBeat
Delcath Systems Q1 2026 earnings preview - MSN
Trading Systems Reacting to (DCTH) Volatility - Stock Traders Daily
Earnings Preview: DCTH to Report Financial Results Pre-market on May 07 - Moomoo
How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance - Yahoo Finance
Delcath Systems (DCTH) to Release Quarterly Earnings on Thursday - MarketBeat
Delcath Systems (DCTH) Q2 2025 earnings summary - Quartr
Do Options Traders Know Something About Delcath Systems Stock We Don't? - MSN
BlackRock (NASDAQ: DCTH) holds 1.73M DELCATH shares, 4.98% - Stock Titan
Implied volatility surging for Delcath Systems stock options - MSN
How Delcath Systems Inc. (DCTH) Affects Rotational Strategy Timing - Stock Traders Daily
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.58%
4.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):